Patients whose surgical wait time was 3 months or more versus less than 3 months had 10-fold increased odds of having a smaller tumor.
Recipients of kidneys from individuals who donated the organs after cardiac death are more likely to experience graft loss and delayed graft function.
Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug.
Decreasing salt intake could decrease the risk of recurrent kidney stones.
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
Large prostates and bladder neck sparing also predict longer time to return of continence.
Findings emerge from a study of hypogonadal men who underwent radiation therapy, surgery, or active surveillance for prostate cancer.
Radiation therapy also is associated with a greater likelihood of fractures.
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.
Patients who underwent debulking had significantly longer overall survival compared with those who did not (median 15.7 vs 10 months).
These same patients, however, had less intense detrusor overactivity, urodynamic evaluation revealed.
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Study documents significant improvements in frequency, urgency, and nocturia.
Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.
Therapy used in less than 5% of cases, even in those with higher clinical stage.
Prostate cancer patients taking proton pump inhibitors also had pathologically higher stage disease.
Patients experienced a sustained decrease in AUA Symptom Score, and 95% of patients report being satisfied or very satisfied with the procedure.
The higher the baseline PSA levels, the greater the risk of being diagnosed with any or significant prostate cancer.
Only this histologic variant occurs at a significantly higher incidence in renal allograft recipients than the non-transplant population.
In particular, no hepatic toxicities emerged during a 52-week phase 3 trial.
Minimally invasive surgery is associated with a lower incidence of bladder neck contracture.
Study documents superior recurrence- and metastasis-free survival compared with cT1b tumors.
Mortality risk decreases with increasingly stringent BPT compared with radical cystectomy.
Reasons are unclear, but use of testosterone and other performance enhance drugs could be a contributing factor.
A biologic effective dose less than 170 Gy2 is associated with a 2-fold increase risk dying from prostate cancer versus higher doses.
The chances of erectile function recovery improved when patients received radiation treatment more than 16 months after surgery.
Cytoreductive nephrectomy (CN) use remained stable in the targeted therapy era, but more patients are receiving a combination of CN and systemic therapy.
In a study, use of the medication was associated with a significant 61% decreased risk.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Kidneys From Octogenarian Donors Show Similar Survival
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)